U.S. market Closed. Opens in 1 day 14 hours 23 minutes

KNSA | Kiniksa Pharmaceuticals, Ltd. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for KNSA we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is passable.

Valuation (31%)

Company Industry
P/E Ratio (TTM) -190.46 -22.08
PEG Ratio (TTM) 0.85 15.66
P/S Ratio (TTM) 5.77 49.38
P/B Ratio (TTM) 4.48 18.85
P/FCF Ratio (TTM) 64.50 -3.07
Price to 5YR AVG Earnings Ratio -27.10 -3.42
Price to 5YR AVG FCF Ratio -22.93 -9.04

Profitability (20%)

Company Industry
ROA (TTM) -1.89% -5.15%
ROE (TTM) -5.10% 16.37%
Net Profit Margin (TTM) -3.02% -2,030.32%
ROIC 5YR AVG 24.10% 15.65%

Growth (52%)

4QTR AVG 3YR AVG 5YR AVG
EPS -1.67% 12.97% 32.25%
Revenue 12.50% N/A 98.80%
Net Income -0.65% -18.12% 13.89%
Cash Flow 125.27% -24.74% 31.89%

Health (56%)

Company Industry
Current Ratio (TTM) 3.57 6.19
Quick Ratio (TTM) 3.16 5.91
D/E Ratio (TTM) 0.03 -15.10
Interest Coverage (TTM) -15.01 -1.60
Piotroski F-Score 4 5
Altman Z-Score 10.64 14.02
LTL to 5YR AVG FCF -0.12 0.18
Shares Outstanding Growth 5YR AVG 22.08% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙